(Total Views: 394)
Posted On: 06/17/2019 9:05:44 AM
Post# of 72
$ARQL News Article - ArQule Announces Preliminary Results from Its Phase 1/2 Study of Miransertib (ARQ 092), in Patients with PIK3CA-related Overgrowth Spectrum (PROS) and Proteus syndrome (PS) in an Oral Presentation at the European Society of Human Genetics Conference https://marketwirenews.com/news-releases/arqu...68612.html
(0)
(0)
My Twitter: WhyteStocks
